Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 5:03 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2761–2784 of 2,912 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control Capsules Clear all

Conditions: Hepatitis C
Interventions: Alisporivir, Peginterferon alfa-2a, Ribavirin, ALV Placebo; Drug
Lead sponsor: Debiopharm International SA; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 1,081 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 32
States / cities: Beverly Hills, California • Oakland, California • San Diego, California + 23 more

Conditions: Uncomplicated Urinary Tract Infections, Urinary Tract Infections
Interventions: GSK3882347, Nitrofurantoin, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 70 Years · Female only
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 15
States / cities: Anniston, Alabama • Lomita, California • Modesto, California + 12 more

Conditions: Malignant Melanoma
Interventions: Pembrolizumab, Lenvatinib, Placebo for lenvatinib; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 674 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 17
States / cities: Los Angeles, California • San Francisco, California • Santa Monica, California + 13 more

Conditions: Gastrointestinal Health, Immune Health, Cardiovascular Health, Digestive Health
Interventions: Bacillus subtilis BS50 spore preparation, Maltodextrin; Dietary Supplement
Lead sponsor: BIO-CAT Microbials, LLC; Industry
Eligibility: 30 Years to 65 Years
Enrollment: 76 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Addison, Illinois

Conditions: Pain
Interventions: Gabapentin, Placebo; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 114 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: HIV Infections, Insomnia
Interventions: Doxepin, Temazepam, Placebo; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 69 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Gastric Ulcer
Interventions: PN400 (VIMOVO), Diclofenac/Misoprostol; Drug
Lead sponsor: POZEN; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Hyperuricemia, Gout, Chronic Kidney Diseases
Interventions: ALLN-346, Placebo; Drug
Lead sponsor: Allena Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 17
States / cities: Birmingham, Alabama • Muscle Shoals, Alabama • Sheffield, Alabama + 12 more

Conditions: Post-Traumatic Stress Disorder
Interventions: Dronabinol, Placebo; Drug
Lead sponsor: Wayne State University; Other
Eligibility: 21 Years to 45 Years
Enrollment: 86 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Lung Cancer Prevention
Interventions: green tea, Polyphenon E, placebo; Dietary Supplement · Drug · Other
Lead sponsor: Sherry Chow; Other
Eligibility: 40 Years to 80 Years
Enrollment: 178 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 3
States / cities: Tucson, Arizona

Conditions: HCV Infection
Interventions: GS-9450, GS-9450 Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 5
States / cities: Anaheim, California • Washington D.C., District of Columbia • Orlando, Florida + 2 more

Conditions: Postprandial Amino Acid Concentrations in Healthy Adults
Interventions: Protease enzyme supplement, Placebo; Dietary Supplement · Other
Lead sponsor: Amplifye; Industry
Eligibility: 45 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Davis, California

Conditions: Healthy
Interventions: crushed garlic clove, garlic powder tablet; Other · Dietary Supplement
Lead sponsor: Silliker, Inc.; Industry
Eligibility: 18 Years to 72 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Orem, Utah

Conditions: Ulcerative Colitis
Interventions: PTG-100, Placebo; Drug
Lead sponsor: Protagonist Therapeutics, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 21
States / cities: Los Angeles, California • Colorado Springs, Colorado • Miami, Florida + 17 more

Conditions: Post Operative Dental Pain
Interventions: acetaminophen Tablet, acetaminophen Caplet, ibuprofen Liquid-filled capsule, Placebo Tablet, Placebo Caplet, Placebo Liquid-filled capsule; Drug
Lead sponsor: Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division; Industry
Eligibility: 17 Years to 50 Years
Enrollment: 420 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Crohn's Disease, Inflammatory Bowel Diseases
Interventions: Fluconazole, Placebo, IL-23 Therapy; Drug · Biological
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: New York, New York

Conditions: Sleep Apnea, Opioid Use, Sleep Disordered Breathing
Interventions: Hyperoxia, Acetazolamide; Other · Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 89 Years
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: End Stage Renal Disease
Interventions: paricalcitol capsules; Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 22
States / cities: Los Angeles, California • Denver, Colorado • Washington D.C., District of Columbia + 18 more

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: GFF MDI (PT 003), GP MDI (PT001), FF MDI (PT005), Open-label tiotropium bromide inhalation (Spiriva® Handihaler®); Drug
Lead sponsor: Pearl Therapeutics, Inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 892 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 110
States / cities: Andalusia, Alabama • Anniston, Alabama • Athens, Alabama + 107 more

Conditions: Knee Osteoarthritis, Blood Loss, Pain, Postoperative
Interventions: Tranexamic Acid Pill, Placebo; Drug
Lead sponsor: Campbell Clinic; Other
Eligibility: 18 Years to 80 Years
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Germantown, Tennessee

Conditions: Schizophrenia
Interventions: BF2.649, Placebo; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 55 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 2
States / cities: Dallas, Texas

Conditions: Microbiome, Immune Function
Interventions: Aloe Vera Extract 1, Control, Aloe Vera Extract 2; Dietary Supplement
Lead sponsor: University of Memphis; Other
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Cocaine Dependence
Interventions: RTI-336 (CTDP 31862); Drug
Lead sponsor: RTI International; Other
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Miramar, Florida

Conditions: Dysbiosis, Gut -microbiota, Microbiome Analysis, Probiotic, Antibiotic Prophylaxis
Interventions: Placebo Capsule, Probiotic with Human Milk Oligosaccharides (HMO); Drug · Dietary Supplement
Lead sponsor: Acibadem Maslak Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Search by objective public record fields.

Efficacy and Safety of Alisporivir Triple Therapy in Chronic Hepatitis C Genotype 1 Treatment-naïve Participants

Safety, Tolerability, Pharmacokinetic and Microbiological Investigation of GSK3882347 in Female Participants With Urinary Tract Infections

Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advance Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)

Effect of Bacillus Subtilis BS50 Supplementation on Gastrointestinal Symptoms in Healthy Adults

Gabapentin as an Adjunct to Paracervical Block for Perioperative Pain Management

The Treatment of Insomnia in Patients With HIV Disease

Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers in High Risk Subjects Compared to Arthrotec

Phase IIa Study of ALLN-346 (Engineered Urate Oxidase) in Subjects With Hyperuricemia, Gout and Chronic Kidney Disease

Cannabinoid Control of Fear Extinction Neural Circuits in Post-traumatic Stress Disorder

Green Tea or Polyphenon E in Preventing Lung Cancer in Former Smokers With Chronic Obstructive Pulmonary Disease

Evaluation of the Safety, Tolerability, Pharmacokinetics, and Activity of GS-9450 in Subjects With Chronic HCV

Effects of P24 on Postprandial Aminoacidemia

Allicin Bioavailability From Garlic Supplements and Garlic Foods

Safety and Efficacy Study of PTG-100 in the Treatment of Moderate to Severe Ulcerative Colitis

Study of Acetaminophen (ACM) in Post-operative Dental Pain

Testing the Role of Anti-fungal Therapy in Improving the Response to Therapies for Crohn's Disease

Sleep Disordered Breathing With Opioid Use

A Study to Evaluate the Safety and Efficacy of Paricalcitol Capsules in Reducing Serum Intact Parathyroid Hormone Levels in End Stage Renal Disease Subjects on Peritoneal Dialysis

Extension Study to Evaluate the Safety and Efficacy of PT003, PT001, and PT005 in Subjects With Moderate to Very Severe COPD, With Spiriva® Handihaler® (PINNACLE 3)

Extended Postoperative Oral Tranexamic Acid in Knee Replacement

Study to Demonstrate Cognitive Enhancing Effects of BF2.649

Comparison Study of Manapol and DaltonMax on Immune Function, Microbiome, and Related Variables in Men and Women

Safety, Tolerability, and Pharmacokinetics of Single, Escalating Oral Doses of RTI-336 in Healthy, Male Subjects

Impact of Probiotics on Gut Microbiome During Antibiotic Prophylaxis in Elective Orthopedic Surgery